Cell Therapy of Infectious Diseases

Dear Colleagues,

CMV and EBV after Hematopoietic Stem Cell Transplantation

The infection or reactivation of latent virus infections, mainly cytomegalovirus (CMV) and Epstein–Barr virus (EBV), is a frequent event (50-80%) and remains a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplants (HSCTs). Healthy seropositive individuals have high frequencies of CMV- and EBV-specific CD4+ and CD8+ T cells, ranging from 0,05% to 1,6% and from 0,5 to 4% of the total T-cell population, respectively, playing a critical role in controlling in these latent viral infections. The immunosurveillance that maintains this latent virus under control is lost during the post-HSCT period. Although a pre-emptive treatment with ganciclovir or foscarnet and, more recently, prophylaxis with letermovir reduces the incidence and mortality of early CMV infections in HSCTs, it may not able to control infection due to refractory or genetic viral resistance (15-20% of patients) or complicated by myelosuppression or nephrotoxicity (6-30% of patients). Furthermore, antivirals do not address the underlying immune defect and, in fact, can also delay the recovery of virus-specific immune responses explaining multiple CMV infections.

SARS-CoV-2 Infections 

Cell therapies have been studied is several clinical trials for the treatment of COVID-19 patients. Mesenchymal stromal cells (MSCs), natural killer (NK) cells and the use of cytotoxic T lymphocytes (CTLs) are currently in phase one and two trials to test their safety and efficacy in COVID-19 patients. Although some (i.e., MSC) have shown some clinical benefit, they have also raised some issues, such as immune rejection, low numbers of cells obtained, the need for T cell expansion under GMP conditions and lack of standardized protocols. NK cells from the innate immune system and T-cell-adaptive immune response are key in eliminating viral infections and controlling the disease; usually, low lymphocyte counts are present in individuals who die of COVID-19. T cell functionality is crucial for killing target infected cells. Adoptive cell therapy with HLA-matched CD45RA^- memory T cells from recovered donors has proved its efficiency in preventing infections in the field of HSCTs as well as SARS-CoV-2 infections.

Fungi and Others

CD45RA- T memory lymphocytes from allogeneic donors were found to also recognize Aspergillus and other fungi.

Adoptive Immunotherapy is a treatment option for unmet medical needs that were investigated and improved on in the last decade. HLA-matched donor lymphocyte infusion demonstrated efficacy in treating COVID-19, EBV, CMV, etc.

This Special Issue aims to review the state-of-the art when using cellular medicaments to treat infections.

Prof. Dr. Bernat Soria
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cell therapy
• infectious diseases
• COVID-19
• cytomegalovirus
• Epstein–Barr virus
• T memory lymphocytes
• mesenchymal stromal cells
• allogeneic adoptive immunotherapy